Filing Flows › Nurix Therapeutics (NRIX) › Q3 FY26
Nurix Therapeutics (NRIX) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Oct 13, 2026
Nurix Therapeutics (NRIX) reported revenue of $673M for the third quarter fiscal 2026 (Q3 FY26), up 85-fold from a year earlier and up 74-fold from the quarter before. Operating margin was 83.1%, net earnings $550M (81.7% of revenue).
Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%, net earnings $550M, operating cash flow $616M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $673M | 74× | 85× |
| Operating profit | $559M | — | — |
| Net earnings | $550M | — | — |
| Operating cash flow | $616M | — | — |
| Free cash flow | $614M | — | — |
What changed
Revenue was $673.1M in Q3 FY26, up 8426% year over year and up 7343% from the previous quarter. License revenue was the largest line at 97% of revenue. Collaboration revenue added $12.0M year over year (up 152%), 2% of the total change.
Operating profit was $559.5M, a 83.1% margin (up 1240.8 points year over year). Total costs grew 14% against revenue growth of 8426%. The fastest-growing cost line was General & admin (+161%). Net earnings were $549.8M. The effective tax rate was 2.4%.
Operating cash flow was $615.6M, 112% of net earnings. Non-cash charges added back $2.1M of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items added $52.9M. Capital expenditures of $1.4M left free cash flow of $614.2M.
Questions
What was Nurix Therapeutics' revenue in the third quarter fiscal 2026?
Nurix Therapeutics (NRIX) reported revenue of $673M for the third quarter fiscal 2026 (Q3 FY26), up 85-fold from a year earlier and up 74-fold from the quarter before.
Was Nurix Therapeutics profitable in the third quarter fiscal 2026?
Operating profit was $559M (83.1% of revenue) and net earnings $550M.
Source: Nurix Therapeutics 10-Q on SEC EDGAR.